Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study
Abstract Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1–6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
---|---|
Enthalten in: |
Rheumatology international - 41(2021), 7 vom: 05. Mai, Seite 1243-1252 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Najim, Mostafa [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
BKL: | |
---|---|
Themen: |
Antiphospholipid antibodies |
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s00296-021-04875-7 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR044179529 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR044179529 | ||
003 | DE-627 | ||
005 | 20230519223832.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210530s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s00296-021-04875-7 |2 doi | |
035 | |a (DE-627)SPR044179529 | ||
035 | |a (SPR)s00296-021-04875-7-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
082 | 0 | 4 | |a 610 |q ASE |
084 | |a 44.83 |2 bkl | ||
100 | 1 | |a Najim, Mostafa |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prevalence and clinical significance of antiphospholipid antibodies in patients with coronavirus disease 2019 admitted to intensive care units: a prospective observational study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Abstract Coronavirus disease 2019 (COVID-19) increases the risk of coagulopathy. Although the presence of antiphospholipid antibodies (aPLs) has been proposed as a possible mechanism of COVID-19-induced coagulopathy, its clinical significance remains uncertain. Therefore, this study aimed to evaluate the prevalence and clinical significance of aPLs among critically ill patients with COVID-19. This prospective observational study included 60 patients with COVID-19 admitted to intensive care units (ICU). The study outcomes included prevalence of aPLs, and a primary composite outcome of all-cause mortality and arterial or venous thrombosis between antiphospholipid-positive and antiphospholipid-negative patients during their ICU stay. Multiple logistic regression was used to assess the influence of aPLs on the primary composite outcome of mortality and thrombosis. A total of 60 critically ill patients were enrolled. Among them, 57 (95%) were men, with a mean age of 52.8 ± 12.2 years, and the majority were from Asia (68%). Twenty-two patients (37%) were found be antiphospholipid-positive; 21 of them were positive for lupus anticoagulant, whereas one patient was positive for anti-β2-glycoprotein IgG/IgM. The composite outcome of mortality and thrombosis during their ICU stay did not differ between antiphospholipid-positive and antiphospholipid-negative patients (4 [18%] vs. 6 [16%], adjusted odds ratio 0.98, 95% confidence interval 0.1–6.7; p value = 0.986). The presence of aPLs does not seem to affect the outcomes of critically ill patients with COVID-19 in terms of all-cause mortality and thrombosis. Therefore, clinicians may not screen critically ill patients with COVID-19 for aPLs unless deemed clinically appropriate. | ||
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Antiphospholipid antibodies |7 (dpeaa)DE-He213 | |
650 | 4 | |a Arterial thrombosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Venous thrombosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Coagulopathy |7 (dpeaa)DE-He213 | |
650 | 4 | |a Critically ill patients |7 (dpeaa)DE-He213 | |
700 | 1 | |a Rahhal, Alaa |e verfasserin |4 aut | |
700 | 1 | |a Khir, Fadi |e verfasserin |4 aut | |
700 | 1 | |a Aljundi, Amer Hussien |e verfasserin |4 aut | |
700 | 1 | |a Abu Yousef, Safae |e verfasserin |4 aut | |
700 | 1 | |a Ibrahim, Feryal |e verfasserin |4 aut | |
700 | 1 | |a Amer, Aliaa |e verfasserin |4 aut | |
700 | 1 | |a Mohamed, Ahmed S. |e verfasserin |4 aut | |
700 | 1 | |a Saleh, Samira |e verfasserin |4 aut | |
700 | 1 | |a Alfaridi, Dekra |e verfasserin |4 aut | |
700 | 1 | |a Mahfouz, Ahmed |e verfasserin |4 aut | |
700 | 1 | |a Alyafei, Sumaya |e verfasserin |4 aut | |
700 | 1 | |a Howady, Faraj |e verfasserin |4 aut | |
700 | 1 | |a Khatib, Mohamad |e verfasserin |4 aut | |
700 | 1 | |a Alemadi, Samar A. |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Rheumatology international |d Berlin : Springer, 1981 |g 41(2021), 7 vom: 05. Mai, Seite 1243-1252 |w (DE-627)SPR00382473X |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
773 | 1 | 8 | |g volume:41 |g year:2021 |g number:7 |g day:05 |g month:05 |g pages:1243-1252 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00296-021-04875-7 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
936 | b | k | |a 44.83 |q ASE |
951 | |a AR | ||
952 | |d 41 |j 2021 |e 7 |b 05 |c 05 |h 1243-1252 |